Lv1
30 积分 2024-04-30 加入
Synthesis and Leukemia Cell Line K562 Inhibitory Activities ofα-(Fluoro-substituted isoindolinone-2-yl)glutarimide Analogues
1天前
已完结
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia
18天前
已完结
Leveraging High-Throughput Experimentation to Drive Pharmaceutical Route Invention: A Four-Step Commercial Synthesis of Branebrutinib (BMS-986195)
19天前
已完结
Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
28天前
已完结
Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
28天前
已关闭
Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
28天前
已关闭
Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies
1个月前
已关闭
Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
1个月前
已完结
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
1个月前
已完结
Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
1个月前
已完结
皖公网安备34019202002308
